Trial Profile
A Phase II, Multicentre, Open, Prospective, Randomised, Parallel-Group, Pharmacodynamic Equivalence Study on Intramuscular Versus Subcutaneous Applications of Triptorelin Pamoate (Pamorelin LA 11.25 mg) in Patients With Advanced Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- Acronyms PAMIS
- Sponsors Ipsen
- 21 Nov 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004139).
- 29 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Jan 2012 Actual patient numbers amended from 100 to 102 as reported by ClinicalTrials.gov.